ClinicalTrials.gg
Not yet recruitingNCT07164092Updated Sep 9, 2025

Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center

A Phase 2/3 interventional study of Atropine 0.05% Eye drops and Placebo ophthalmic solution in Myopia, sponsored by Mansoura University. Not yet recruiting. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Mansoura University · Phase 2/3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Planned enrollment
45th of 54
45 · median 144
Started
2025
with 4 others
Phase 2/3
3 of 54
1 open now
Primary completion
2027-09
later than 15 of 23 live
Registered
45th of 54
by date

Among the 54 studies testing atropine in Myopia, this one is the 45th largest by planned enrollment, is one of 5 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 15 of the 23 other live ones, and was the 45th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate the efficacy and safety of low-dose topical atropine sulphate (0.05%), a non-selective muscarinic antagonist, in slowing the progression of myopia and ocular axial elongation in children. The study will be conducted at Mansoura Ophthalmic Center, Mansoura University, Egypt, from October 2025 to october 2027.

Eligible participants are myopic children attending the outpatient clinic during the study period. Participants will be stratified into three groups according to baseline myopia severity (low, moderate, and high). Each child will be randomized to receive one drop of atropine 0.05% in one eye and one drop of placebo in the fellow eye nightly for 24 months. The allocation of treatment to right or left eye will be randomized to avoid laterality bias.

Study Outcomes

  • Primary Outcome

    o Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation.

  • Secondary Outcomes

    • Change in spherical equivalent refraction (SER), measured by cycloplegic autorefraction using a Topcon KR-800 autorefractor after standard cycloplegia with cyclopentolate 1%.
    • Best-corrected distance visual acuity (BCVA).
  • Sample Size

The primary endpoint of this trial is the change in ocular axial length (AL) over 24 months, analyzed as a paired comparison between the atropine-treated and placebo-treated eyes within each child.

Sample size estimation was based on previously published data reporting mean axial elongation of 0.115 ± 0.11 mm in atropine-treated eyes compared with 0.303 ± 0.12 mm in placebo-treated eyes, yielding a mean difference of 0.188 mm. Assuming an inter-eye correlation of 0.6, the standard deviation of the paired difference is estimated at approximately 0.10 mm, giving an effect size of d = 1.88. Using a two-tailed paired t-test with α = 0.05 and 90% power, the minimum required sample size is 12 children.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • Atropine, Myopia, Axial elongation
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Myopia of at least -1.0 D in both eyes, astigmatism of less than 2.0 D, anisometropia of objective spherical equivalent ≤ 1.50 D.
  • Documented myopic progression of at least 0.5 D in the past one year.

Exclusion criteria

Exclusion Criteria:

  • Children with ocular or systemic diseases that potentially influence myopia or refractive power.
  • Ocular diseases, e.g., cataracts, glaucoma
  • Posterior segment hereditary and acquired pathological disorders.
  • History of any previous ocular surgery.
  • History of any ocular injuries.
  • Previous use of interventions (such as atropine, pirenzepine, orthokeratology lens, or other optical methods) for myopia control
  • Allergy to atropine, cyclopentolate or benzalkonium chloride
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Atropine 0.05% Eye

    The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.

    Drug: Atropine 0.05% Eye drops

  • Placebo comparator
    Placebo Eye

    The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.

    Drug: Placebo ophthalmic solution

Interventions

  • DrugAtropineStudies of AtropineAtropine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The randomized eye will receive one drop of atropine sulphate 0.05% nightly for 24 months.

  • DrugPlacebo ophthalmic solution

    The fellow eye will receive one drop of placebo (vehicle solution without active drug) nightly for 24 months.

06

What researchers measure

Primary outcomes

  1. Change in ocular axial length (AL)

    Change in ocular axial length (AL) from baseline to 24 months, measured with a NIDEK AL-scan optical biometer (average of five readings within a deviation of ≤0.05 mm). This parameter was used for sample size estimation

    Time frame: 2 years

Secondary outcomes

  1. Change in spherical equivalent refraction (SER

    Change in spherical equivalent refraction (SER), measured by cycloplegic autorefraction using a Topcon KR-800 autorefractor after standard cycloplegia with cyclopentolate 1%.

    Time frame: 24 months

  2. Best-corrected distance visual acuity (BCVA).

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — I have not decided yet

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2025
First posted
Sep 9, 2025
StartEst.
Sep 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07164092
Responsible party
Ghada Allam (Lecturer of Ophthalmology, Mansoura University) — Principal investigator
First posted
Sep 9, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 9, 2025

Study contacts

Ghada H. Allam, Dr
Contact
drghada_allam@mans.edu.eg
+201062838323

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion